Global Spinal Muscular Atrophy Medicine Market Insights and Forecast to 2028

Publisher Name :
Date: 17-Feb-2022
No. of pages: 113
Inquire Before Buying

Spinal Muscular Atrophy Medicine market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Spinal Muscular Atrophy Medicine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type

- LMI-070

- ND-602

- NT-1654

- Nusinersen

- NXD-30001

- Others

Segment by Application

- Hospital

- Clinic

- Others

By Company

- Astellas Pharma Inc.

- AveXis, Inc.

- Bioblast Pharma Ltd.

- Cytokinetics, Inc. 24

- F. Hoffmann-La Roche Ltd.

- Genethon

- Genzyme Corporation

- GMP-Orphan SAS

- Ionis Pharmaceuticals, Inc.

- Longevity Biotech, Inc

- Neurodyn Inc.

- Neurotune AG

- Novartis AG

- Sarepta Therapeutics, Inc.

- Voyager Therapeutics, Inc.

- Vybion, Inc.

- WAVE Life Sciences Ltd.

By Region

- North America

- - U.S.

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - India

- - Australia

- - Taiwan

- - Indonesia

- - Thailand

- - Malaysia

- - Philippines

- - Vietnam

- Latin America

- - Mexico

- - Brazil

- - Argentina

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - U.A.E

Global Spinal Muscular Atrophy Medicine Market Insights and Forecast to 2028

Table of Contents
1 Study Coverage
1.1 Spinal Muscular Atrophy Medicine Product Introduction
1.2 Market by Type
1.2.1 Global Spinal Muscular Atrophy Medicine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 LMI-070
1.2.3 ND-602
1.2.4 NT-1654
1.2.5 Nusinersen
1.2.6 NXD-30001
1.2.7 Others
1.3 Market by Application
1.3.1 Global Spinal Muscular Atrophy Medicine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Spinal Muscular Atrophy Medicine Sales Estimates and Forecasts 2017-2028
2.2 Global Spinal Muscular Atrophy Medicine Revenue Estimates and Forecasts 2017-2028
2.3 Global Spinal Muscular Atrophy Medicine Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Spinal Muscular Atrophy Medicine Sales by Region
2.4.1 Global Spinal Muscular Atrophy Medicine Sales by Region (2017-2022)
2.4.2 Global Sales Spinal Muscular Atrophy Medicine by Region (2023-2028)
2.5 Global Spinal Muscular Atrophy Medicine Revenue by Region
2.5.1 Global Spinal Muscular Atrophy Medicine Revenue by Region (2017-2022)
2.5.2 Global Spinal Muscular Atrophy Medicine Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Spinal Muscular Atrophy Medicine Sales by Manufacturers
3.1.1 Global Top Spinal Muscular Atrophy Medicine Manufacturers by Sales (2017-2022)
3.1.2 Global Spinal Muscular Atrophy Medicine Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Spinal Muscular Atrophy Medicine in 2021
3.2 Global Spinal Muscular Atrophy Medicine Revenue by Manufacturers
3.2.1 Global Spinal Muscular Atrophy Medicine Revenue by Manufacturers (2017-2022)
3.2.2 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Spinal Muscular Atrophy Medicine Revenue in 2021
3.3 Global Spinal Muscular Atrophy Medicine Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Spinal Muscular Atrophy Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Spinal Muscular Atrophy Medicine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Spinal Muscular Atrophy Medicine Sales by Type
4.1.1 Global Spinal Muscular Atrophy Medicine Historical Sales by Type (2017-2022)
4.1.2 Global Spinal Muscular Atrophy Medicine Forecasted Sales by Type (2023-2028)
4.1.3 Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2017-2028)
4.2 Global Spinal Muscular Atrophy Medicine Revenue by Type
4.2.1 Global Spinal Muscular Atrophy Medicine Historical Revenue by Type (2017-2022)
4.2.2 Global Spinal Muscular Atrophy Medicine Forecasted Revenue by Type (2023-2028)
4.2.3 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2017-2028)
4.3 Global Spinal Muscular Atrophy Medicine Price by Type
4.3.1 Global Spinal Muscular Atrophy Medicine Price by Type (2017-2022)
4.3.2 Global Spinal Muscular Atrophy Medicine Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Spinal Muscular Atrophy Medicine Sales by Application
5.1.1 Global Spinal Muscular Atrophy Medicine Historical Sales by Application (2017-2022)
5.1.2 Global Spinal Muscular Atrophy Medicine Forecasted Sales by Application (2023-2028)
5.1.3 Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2017-2028)
5.2 Global Spinal Muscular Atrophy Medicine Revenue by Application
5.2.1 Global Spinal Muscular Atrophy Medicine Historical Revenue by Application (2017-2022)
5.2.2 Global Spinal Muscular Atrophy Medicine Forecasted Revenue by Application (2023-2028)
5.2.3 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2017-2028)
5.3 Global Spinal Muscular Atrophy Medicine Price by Application
5.3.1 Global Spinal Muscular Atrophy Medicine Price by Application (2017-2022)
5.3.2 Global Spinal Muscular Atrophy Medicine Price Forecast by Application (2023-2028)
6 North America
6.1 North America Spinal Muscular Atrophy Medicine Market Size by Type
6.1.1 North America Spinal Muscular Atrophy Medicine Sales by Type (2017-2028)
6.1.2 North America Spinal Muscular Atrophy Medicine Revenue by Type (2017-2028)
6.2 North America Spinal Muscular Atrophy Medicine Market Size by Application
6.2.1 North America Spinal Muscular Atrophy Medicine Sales by Application (2017-2028)
6.2.2 North America Spinal Muscular Atrophy Medicine Revenue by Application (2017-2028)
6.3 North America Spinal Muscular Atrophy Medicine Market Size by Country
6.3.1 North America Spinal Muscular Atrophy Medicine Sales by Country (2017-2028)
6.3.2 North America Spinal Muscular Atrophy Medicine Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Spinal Muscular Atrophy Medicine Market Size by Type
7.1.1 Europe Spinal Muscular Atrophy Medicine Sales by Type (2017-2028)
7.1.2 Europe Spinal Muscular Atrophy Medicine Revenue by Type (2017-2028)
7.2 Europe Spinal Muscular Atrophy Medicine Market Size by Application
7.2.1 Europe Spinal Muscular Atrophy Medicine Sales by Application (2017-2028)
7.2.2 Europe Spinal Muscular Atrophy Medicine Revenue by Application (2017-2028)
7.3 Europe Spinal Muscular Atrophy Medicine Market Size by Country
7.3.1 Europe Spinal Muscular Atrophy Medicine Sales by Country (2017-2028)
7.3.2 Europe Spinal Muscular Atrophy Medicine Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Spinal Muscular Atrophy Medicine Market Size by Type
8.1.1 Asia Pacific Spinal Muscular Atrophy Medicine Sales by Type (2017-2028)
8.1.2 Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Type (2017-2028)
8.2 Asia Pacific Spinal Muscular Atrophy Medicine Market Size by Application
8.2.1 Asia Pacific Spinal Muscular Atrophy Medicine Sales by Application (2017-2028)
8.2.2 Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Application (2017-2028)
8.3 Asia Pacific Spinal Muscular Atrophy Medicine Market Size by Region
8.3.1 Asia Pacific Spinal Muscular Atrophy Medicine Sales by Region (2017-2028)
8.3.2 Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Spinal Muscular Atrophy Medicine Market Size by Type
9.1.1 Latin America Spinal Muscular Atrophy Medicine Sales by Type (2017-2028)
9.1.2 Latin America Spinal Muscular Atrophy Medicine Revenue by Type (2017-2028)
9.2 Latin America Spinal Muscular Atrophy Medicine Market Size by Application
9.2.1 Latin America Spinal Muscular Atrophy Medicine Sales by Application (2017-2028)
9.2.2 Latin America Spinal Muscular Atrophy Medicine Revenue by Application (2017-2028)
9.3 Latin America Spinal Muscular Atrophy Medicine Market Size by Country
9.3.1 Latin America Spinal Muscular Atrophy Medicine Sales by Country (2017-2028)
9.3.2 Latin America Spinal Muscular Atrophy Medicine Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Spinal Muscular Atrophy Medicine Market Size by Type
10.1.1 Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Type (2017-2028)
10.1.2 Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Type (2017-2028)
10.2 Middle East and Africa Spinal Muscular Atrophy Medicine Market Size by Application
10.2.1 Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Application (2017-2028)
10.2.2 Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Application (2017-2028)
10.3 Middle East and Africa Spinal Muscular Atrophy Medicine Market Size by Country
10.3.1 Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country (2017-2028)
10.3.2 Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Astellas Pharma Inc.
11.1.1 Astellas Pharma Inc. Corporation Information
11.1.2 Astellas Pharma Inc. Overview
11.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Astellas Pharma Inc. Recent Developments
11.2 AveXis, Inc.
11.2.1 AveXis, Inc. Corporation Information
11.2.2 AveXis, Inc. Overview
11.2.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 AveXis, Inc. Spinal Muscular Atrophy Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 AveXis, Inc. Recent Developments
11.3 Bioblast Pharma Ltd.
11.3.1 Bioblast Pharma Ltd. Corporation Information
11.3.2 Bioblast Pharma Ltd. Overview
11.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Bioblast Pharma Ltd. Recent Developments
11.4 Cytokinetics, Inc. 24
11.4.1 Cytokinetics, Inc. 24 Corporation Information
11.4.2 Cytokinetics, Inc. 24 Overview
11.4.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Cytokinetics, Inc. 24 Recent Developments
11.5 F. Hoffmann-La Roche Ltd.
11.5.1 F. Hoffmann-La Roche Ltd. Corporation Information
11.5.2 F. Hoffmann-La Roche Ltd. Overview
11.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 F. Hoffmann-La Roche Ltd. Recent Developments
11.6 Genethon
11.6.1 Genethon Corporation Information
11.6.2 Genethon Overview
11.6.3 Genethon Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Genethon Spinal Muscular Atrophy Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Genethon Recent Developments
11.7 Genzyme Corporation
11.7.1 Genzyme Corporation Corporation Information
11.7.2 Genzyme Corporation Overview
11.7.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Genzyme Corporation Spinal Muscular Atrophy Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Genzyme Corporation Recent Developments
11.8 GMP-Orphan SAS
11.8.1 GMP-Orphan SAS Corporation Information
11.8.2 GMP-Orphan SAS Overview
11.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 GMP-Orphan SAS Recent Developments
11.9 Ionis Pharmaceuticals, Inc.
11.9.1 Ionis Pharmaceuticals, Inc. Corporation Information
11.9.2 Ionis Pharmaceuticals, Inc. Overview
11.9.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Ionis Pharmaceuticals, Inc. Recent Developments
11.10 Longevity Biotech, Inc
11.10.1 Longevity Biotech, Inc Corporation Information
11.10.2 Longevity Biotech, Inc Overview
11.10.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Longevity Biotech, Inc Recent Developments
11.11 Neurodyn Inc.
11.11.1 Neurodyn Inc. Corporation Information
11.11.2 Neurodyn Inc. Overview
11.11.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Neurodyn Inc. Recent Developments
11.12 Neurotune AG
11.12.1 Neurotune AG Corporation Information
11.12.2 Neurotune AG Overview
11.12.3 Neurotune AG Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Neurotune AG Spinal Muscular Atrophy Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Neurotune AG Recent Developments
11.13 Novartis AG
11.13.1 Novartis AG Corporation Information
11.13.2 Novartis AG Overview
11.13.3 Novartis AG Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Novartis AG Spinal Muscular Atrophy Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Novartis AG Recent Developments
11.14 Sarepta Therapeutics, Inc.
11.14.1 Sarepta Therapeutics, Inc. Corporation Information
11.14.2 Sarepta Therapeutics, Inc. Overview
11.14.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Sarepta Therapeutics, Inc. Recent Developments
11.15 Voyager Therapeutics, Inc.
11.15.1 Voyager Therapeutics, Inc. Corporation Information
11.15.2 Voyager Therapeutics, Inc. Overview
11.15.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Voyager Therapeutics, Inc. Recent Developments
11.16 Vybion, Inc.
11.16.1 Vybion, Inc. Corporation Information
11.16.2 Vybion, Inc. Overview
11.16.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Vybion, Inc. Spinal Muscular Atrophy Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Vybion, Inc. Recent Developments
11.17 WAVE Life Sciences Ltd.
11.17.1 WAVE Life Sciences Ltd. Corporation Information
11.17.2 WAVE Life Sciences Ltd. Overview
11.17.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 WAVE Life Sciences Ltd. Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Spinal Muscular Atrophy Medicine Industry Chain Analysis
12.2 Spinal Muscular Atrophy Medicine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Spinal Muscular Atrophy Medicine Production Mode & Process
12.4 Spinal Muscular Atrophy Medicine Sales and Marketing
12.4.1 Spinal Muscular Atrophy Medicine Sales Channels
12.4.2 Spinal Muscular Atrophy Medicine Distributors
12.5 Spinal Muscular Atrophy Medicine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Spinal Muscular Atrophy Medicine Industry Trends
13.2 Spinal Muscular Atrophy Medicine Market Drivers
13.3 Spinal Muscular Atrophy Medicine Market Challenges
13.4 Spinal Muscular Atrophy Medicine Market Restraints
14 Key Findings in The Global Spinal Muscular Atrophy Medicine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Spinal Muscular Atrophy Medicine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of LMI-070
Table 3. Major Manufacturers of ND-602
Table 4. Major Manufacturers of NT-1654
Table 5. Major Manufacturers of Nusinersen
Table 6. Major Manufacturers of NXD-30001
Table 7. Major Manufacturers of Others
Table 8. Global Spinal Muscular Atrophy Medicine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 9. Global Spinal Muscular Atrophy Medicine Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 10. Global Spinal Muscular Atrophy Medicine Sales by Region (2017-2022) & (K Pcs)
Table 11. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2017-2022)
Table 12. Global Spinal Muscular Atrophy Medicine Sales by Region (2023-2028) & (K Pcs)
Table 13. Global Spinal Muscular Atrophy Medicine Sales Market Share by Region (2023-2028)
Table 14. Global Spinal Muscular Atrophy Medicine Revenue by Region (2017-2022) & (US$ Million)
Table 15. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2017-2022)
Table 16. Global Spinal Muscular Atrophy Medicine Revenue by Region (2023-2028) & (US$ Million)
Table 17. Global Spinal Muscular Atrophy Medicine Revenue Market Share by Region (2023-2028)
Table 18. Global Spinal Muscular Atrophy Medicine Sales by Manufacturers (2017-2022) & (K Pcs)
Table 19. Global Spinal Muscular Atrophy Medicine Sales Share by Manufacturers (2017-2022)
Table 20. Global Spinal Muscular Atrophy Medicine Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 21. Global Spinal Muscular Atrophy Medicine Revenue Share by Manufacturers (2017-2022)
Table 22. Spinal Muscular Atrophy Medicine Price by Manufacturers (2017-2022) &(USD/Pcs)
Table 23. Global Spinal Muscular Atrophy Medicine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Spinal Muscular Atrophy Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Spinal Muscular Atrophy Medicine as of 2021)
Table 25. Spinal Muscular Atrophy Medicine Manufacturing Base Distribution and Headquarters
Table 26. Manufacturers Spinal Muscular Atrophy Medicine Product Offered
Table 27. Date of Manufacturers Enter into Spinal Muscular Atrophy Medicine Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Spinal Muscular Atrophy Medicine Sales by Type (2017-2022) & (K Pcs)
Table 30. Global Spinal Muscular Atrophy Medicine Sales by Type (2023-2028) & (K Pcs)
Table 31. Global Spinal Muscular Atrophy Medicine Sales Share by Type (2017-2022)
Table 32. Global Spinal Muscular Atrophy Medicine Sales Share by Type (2023-2028)
Table 33. Global Spinal Muscular Atrophy Medicine Revenue by Type (2017-2022) & (US$ Million)
Table 34. Global Spinal Muscular Atrophy Medicine Revenue by Type (2023-2028) & (US$ Million)
Table 35. Global Spinal Muscular Atrophy Medicine Revenue Share by Type (2017-2022)
Table 36. Global Spinal Muscular Atrophy Medicine Revenue Share by Type (2023-2028)
Table 37. Spinal Muscular Atrophy Medicine Price by Type (2017-2022) & (USD/Pcs)
Table 38. Global Spinal Muscular Atrophy Medicine Price Forecast by Type (2023-2028) & (USD/Pcs)
Table 39. Global Spinal Muscular Atrophy Medicine Sales by Application (2017-2022) & (K Pcs)
Table 40. Global Spinal Muscular Atrophy Medicine Sales by Application (2023-2028) & (K Pcs)
Table 41. Global Spinal Muscular Atrophy Medicine Sales Share by Application (2017-2022)
Table 42. Global Spinal Muscular Atrophy Medicine Sales Share by Application (2023-2028)
Table 43. Global Spinal Muscular Atrophy Medicine Revenue by Application (2017-2022) & (US$ Million)
Table 44. Global Spinal Muscular Atrophy Medicine Revenue by Application (2023-2028) & (US$ Million)
Table 45. Global Spinal Muscular Atrophy Medicine Revenue Share by Application (2017-2022)
Table 46. Global Spinal Muscular Atrophy Medicine Revenue Share by Application (2023-2028)
Table 47. Spinal Muscular Atrophy Medicine Price by Application (2017-2022) & (USD/Pcs)
Table 48. Global Spinal Muscular Atrophy Medicine Price Forecast by Application (2023-2028) & (USD/Pcs)
Table 49. North America Spinal Muscular Atrophy Medicine Sales by Type (2017-2022) & (K Pcs)
Table 50. North America Spinal Muscular Atrophy Medicine Sales by Type (2023-2028) & (K Pcs)
Table 51. North America Spinal Muscular Atrophy Medicine Revenue by Type (2017-2022) & (US$ Million)
Table 52. North America Spinal Muscular Atrophy Medicine Revenue by Type (2023-2028) & (US$ Million)
Table 53. North America Spinal Muscular Atrophy Medicine Sales by Application (2017-2022) & (K Pcs)
Table 54. North America Spinal Muscular Atrophy Medicine Sales by Application (2023-2028) & (K Pcs)
Table 55. North America Spinal Muscular Atrophy Medicine Revenue by Application (2017-2022) & (US$ Million)
Table 56. North America Spinal Muscular Atrophy Medicine Revenue by Application (2023-2028) & (US$ Million)
Table 57. North America Spinal Muscular Atrophy Medicine Sales by Country (2017-2022) & (K Pcs)
Table 58. North America Spinal Muscular Atrophy Medicine Sales by Country (2023-2028) & (K Pcs)
Table 59. North America Spinal Muscular Atrophy Medicine Revenue by Country (2017-2022) & (US$ Million)
Table 60. North America Spinal Muscular Atrophy Medicine Revenue by Country (2023-2028) & (US$ Million)
Table 61. Europe Spinal Muscular Atrophy Medicine Sales by Type (2017-2022) & (K Pcs)
Table 62. Europe Spinal Muscular Atrophy Medicine Sales by Type (2023-2028) & (K Pcs)
Table 63. Europe Spinal Muscular Atrophy Medicine Revenue by Type (2017-2022) & (US$ Million)
Table 64. Europe Spinal Muscular Atrophy Medicine Revenue by Type (2023-2028) & (US$ Million)
Table 65. Europe Spinal Muscular Atrophy Medicine Sales by Application (2017-2022) & (K Pcs)
Table 66. Europe Spinal Muscular Atrophy Medicine Sales by Application (2023-2028) & (K Pcs)
Table 67. Europe Spinal Muscular Atrophy Medicine Revenue by Application (2017-2022) & (US$ Million)
Table 68. Europe Spinal Muscular Atrophy Medicine Revenue by Application (2023-2028) & (US$ Million)
Table 69. Europe Spinal Muscular Atrophy Medicine Sales by Country (2017-2022) & (K Pcs)
Table 70. Europe Spinal Muscular Atrophy Medicine Sales by Country (2023-2028) & (K Pcs)
Table 71. Europe Spinal Muscular Atrophy Medicine Revenue by Country (2017-2022) & (US$ Million)
Table 72. Europe Spinal Muscular Atrophy Medicine Revenue by Country (2023-2028) & (US$ Million)
Table 73. Asia Pacific Spinal Muscular Atrophy Medicine Sales by Type (2017-2022) & (K Pcs)
Table 74. Asia Pacific Spinal Muscular Atrophy Medicine Sales by Type (2023-2028) & (K Pcs)
Table 75. Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Type (2017-2022) & (US$ Million)
Table 76. Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Type (2023-2028) & (US$ Million)
Table 77. Asia Pacific Spinal Muscular Atrophy Medicine Sales by Application (2017-2022) & (K Pcs)
Table 78. Asia Pacific Spinal Muscular Atrophy Medicine Sales by Application (2023-2028) & (K Pcs)
Table 79. Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Application (2017-2022) & (US$ Million)
Table 80. Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Application (2023-2028) & (US$ Million)
Table 81. Asia Pacific Spinal Muscular Atrophy Medicine Sales by Region (2017-2022) & (K Pcs)
Table 82. Asia Pacific Spinal Muscular Atrophy Medicine Sales by Region (2023-2028) & (K Pcs)
Table 83. Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Region (2017-2022) & (US$ Million)
Table 84. Asia Pacific Spinal Muscular Atrophy Medicine Revenue by Region (2023-2028) & (US$ Million)
Table 85. Latin America Spinal Muscular Atrophy Medicine Sales by Type (2017-2022) & (K Pcs)
Table 86. Latin America Spinal Muscular Atrophy Medicine Sales by Type (2023-2028) & (K Pcs)
Table 87. Latin America Spinal Muscular Atrophy Medicine Revenue by Type (2017-2022) & (US$ Million)
Table 88. Latin America Spinal Muscular Atrophy Medicine Revenue by Type (2023-2028) & (US$ Million)
Table 89. Latin America Spinal Muscular Atrophy Medicine Sales by Application (2017-2022) & (K Pcs)
Table 90. Latin America Spinal Muscular Atrophy Medicine Sales by Application (2023-2028) & (K Pcs)
Table 91. Latin America Spinal Muscular Atrophy Medicine Revenue by Application (2017-2022) & (US$ Million)
Table 92. Latin America Spinal Muscular Atrophy Medicine Revenue by Application (2023-2028) & (US$ Million)
Table 93. Latin America Spinal Muscular Atrophy Medicine Sales by Country (2017-2022) & (K Pcs)
Table 94. Latin America Spinal Muscular Atrophy Medicine Sales by Country (2023-2028) & (K Pcs)
Table 95. Latin America Spinal Muscular Atrophy Medicine Revenue by Country (2017-2022) & (US$ Million)
Table 96. Latin America Spinal Muscular Atrophy Medicine Revenue by Country (2023-2028) & (US$ Million)
Table 97. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Type (2017-2022) & (K Pcs)
Table 98. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Type (2023-2028) & (K Pcs)
Table 99. Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Type (2017-2022) & (US$ Million)
Table 100. Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Type (2023-2028) & (US$ Million)
Table 101. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Application (2017-2022) & (K Pcs)
Table 102. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Application (2023-2028) & (K Pcs)
Table 103. Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Application (2017-2022) & (US$ Million)
Table 104. Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Application (2023-2028) & (US$ Million)
Table 105. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country (2017-2022) & (K Pcs)
Table 106. Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country (2023-2028) & (K Pcs)
Table 107. Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Country (2017-2022) & (US$ Million)
Table 108. Middle East and Africa Spinal Muscular Atrophy Medicine Revenue by Country (2023-2028) & (US$ Million)
Table 109. Astellas Pharma Inc. Corporation Information
Table 110. Astellas Pharma Inc. Description and Major Businesses
Table 111. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 112. Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Model Numbers, Pictures, Descriptions and Specifications
Table 113. Astellas Pharma Inc. Recent Developments
Table 114. AveXis, Inc. Corporation Information
Table 115. AveXis, Inc. Description and Major Businesses
Table 116. AveXis, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 117. AveXis, Inc. Spinal Muscular Atrophy Medicine Product Model Numbers, Pictures, Descriptions and Specifications
Table 118. AveXis, Inc. Recent Developments
Table 119. Bioblast Pharma Ltd. Corporation Information
Table 120. Bioblast Pharma Ltd. Description and Major Businesses
Table 121. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 122. Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Model Numbers, Pictures, Descriptions and Specifications
Table 123. Bioblast Pharma Ltd. Recent Developments
Table 124. Cytokinetics, Inc. 24 Corporation Information
Table 125. Cytokinetics, Inc. 24 Description and Major Businesses
Table 126. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 127. Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Model Numbers, Pictures, Descriptions and Specifications
Table 128. Cytokinetics, Inc. 24 Recent Developments
Table 129. F. Hoffmann-La Roche Ltd. Corporation Information
Table 130. F. Hoffmann-La Roche Ltd. Description and Major Businesses
Table 131. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 132. F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Model Numbers, Pictures, Descriptions and Specifications
Table 133. F. Hoffmann-La Roche Ltd. Recent Developments
Table 134. Genethon Corporation Information
Table 135. Genethon Description and Major Businesses
Table 136. Genethon Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 137. Genethon Spinal Muscular Atrophy Medicine Product Model Numbers, Pictures, Descriptions and Specifications
Table 138. Genethon Recent Developments
Table 139. Genzyme Corporation Corporation Information
Table 140. Genzyme Corporation Description and Major Businesses
Table 141. Genzyme Corporation Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 142. Genzyme Corporation Spinal Muscular Atrophy Medicine Product Model Numbers, Pictures, Descriptions and Specifications
Table 143. Genzyme Corporation Recent Developments
Table 144. GMP-Orphan SAS Corporation Information
Table 145. GMP-Orphan SAS Description and Major Businesses
Table 146. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 147. GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Model Numbers, Pictures, Descriptions and Specifications
Table 148. GMP-Orphan SAS Recent Developments
Table 149. Ionis Pharmaceuticals, Inc. Corporation Information
Table 150. Ionis Pharmaceuticals, Inc. Description and Major Businesses
Table 151. Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 152. I
  • Global Antioxidant Vitamins Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100
    The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
  • Global Clavulanate Potassium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
  • Global Amoxicillin Sodium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84
    The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
  • Global Melatonin Supplements Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
  • Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
  • Global Sleeping Pills Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94
    The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Zinc Oral Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
  • Global Zinc Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
  • Global Anti-Infectives Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs